Browsing by Author "Yamatani, Kotoko"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Comparison of the clinical performance and usefulness of five SARS-CoV-2 antibody tests
    (PloS, 2021) Wakita, Mitsuru; Idei, Mayumi; Saito, Kaori; Horiuchi, Yuki; Yamatani, Kotoko; Ishikawa, Suzuka; Yamamoto, Takamasa; Igawa, Gene; Hinata, Masanobu; Kadota, Katsuhiko; Kurosawa, Taro; Takahashi, Sho; Saito, Takumi; Misawa, Shigeki; Akazawa, Chihiro; Naito, Toshio; Milda, Takashi; Takahashi, Kazuhisa; Ai, Tomohiko; Tabe, Yoko; Medicine, School of Medicine
    We examined the usefulness of five COVID-19 antibody detection tests using 114 serum samples at various time points from 34 Japanese COVID-19 patients. We examined Elecsys Anti-SARS-CoV-2 from Roche, and four immunochromatography tests from Hangzhou Laihe Biotech, Artron Laboratories, Chil, and Nadal. In the first week after onset, Elecsys had 40% positivity in Group S (severe cases) but was negative in Group M (mild-moderate cases). The immunochromatography kits showed 40–60% and 0–8% positivity in Groups S and M, respectively. In the second week, Elecsys showed 75% and 50% positivity, and the immunochromatography tests showed 5–80% and 50–75% positivity in Groups S and M, respectively. After the third week, Elecsys showed 100% positivity in both groups. The immunochromatography kits showed 100% positivity in Group S. In Group M, positivity decreased to 50% for Chil and 75–89% for Artron and Lyher. Elecsys and immunochromatography kits had 91–100% specificity. Elecsys had comparable chronological change of cut-off index values in the two groups from the second week to the sixth week. The current SARS-CoV-2 antibody detection tests do not provide meaningful interpretation of severity and infection status. Its use might be limited to short-term epidemiological studies.
  • Thumbnail Image
    Item
    Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML
    (Elsevier, 2022) Yamatani, Kotoko; Ai, Tomohiko; Saito, Kaori; Suzuki, Koya; Hori, Atsushi; Kinjo, Sonoko; Ikeo, Kazuho; Ruvolo, Vivian; Zhang, Weiguo; Mak, Po Yee; Kaczkowski, Bogumil; Harada, Hironori; Katayama, Kazuhiro; Sugimoto, Yoshikazu; Myslinski, Jered; Hato, Takashi; Miida, Takashi; Konopleva, Marina; Hayashizaki, Yoshihide; Carter, Bing Z.; Tabe, Yoko; Andreeff, Michael; Medicine, School of Medicine
    Tyrosine kinase inhibitors (TKIs) are established drugs in the therapy of FLT3-ITD mutated acute myeloid leukemia (AML). However, acquired mutations, such as D835 in the tyrosine kinase domain (FLT3-ITD/D835), can induce resistance to TKIs. A cap analysis gene expression (CAGE) technology revealed that the gene expression of BCL2A1 transcription start sites was increased in primary AML cells bearing FLT3-ITD/D835 compared to FLT3-ITD. Overexpression of BCL2A1 attenuated the sensitivity to quizartinib, a type II TKI, and venetoclax, a selective BCL2 inhibitor, in AML cell lines. However, a type I TKI, gilteritinib, inhibited the expression of BCL2A1 through inactivation of STAT5 and alleviated TKI resistance of FLT3-ITD/D835. The combination of gilteritinib and venetoclax showed synergistic effects in the FLT3-ITD/D835 positive AML cells. The promoter region of BCL2A1 contains a BRD4 binding site. Thus, the blockade of BRD4 with a BET inhibitor (CPI-0610) downregulated BCL2A1 in FLT3-mutated AML cells and extended profound suppression of FLT3-ITD/D835 mutant cells. Therefore, we propose that BCL2A1 has the potential to be a novel therapeutic target in treating FLT3-ITD/D835 mutated AML.